Skip to main content

Table 2 Post-exercise outcomes compared to baseline

From: Effects of Methylsulfonylmethane (MSM) on exercise-induced oxidative stress, muscle damage, and pain following a half-marathon: a double-blind, randomized, placebo-controlled trial

Outcome N   T0 (Base) T1 (15 Min.) T2 (90 Min.) T3 (1 Day) T4 (2 Day)
8OHdG (ng/mL) 22 Mean ± SD 9.06 ± 3.28 10.59 ± 4.00 10.25 ± 3.57 8.60 ± 2.98 8.50 ± 2.50
ΔBaseline   1.53**
(0.86–2.20)
1.19*
(0.37–2.01)
−0.46
(−1.18–0.26)
−0.57
(−1.27–0.13)
MDA (μM) 22 Mean ± SD 17.4 ± 4.7 24.7 ± 7.7 18.3 ± 6.1 16.2 ± 4.3 17.3 ± 4.7
ΔBaseline   7.3**
(3.9–10.7)
0.9
(−1.8–3.6)
−1.2
(−2.9–0.5)
−0.1
(−2.2–1.9)
logCK (U/L) 22 Mean ± SD 1.99 ± 0.20 2.25 ± 0.26 2.32 ± 0.28 2.58 ± 0.46 2.35 ± 0.42
ΔBaseline   0.26**
(0.13–0.38)
0.33**
(0.20–0.46)
0.59**
(0.39–0.79)
0.36**
(0.17–0.54)
LDH (U/L) 22 Mean ± SD 158.2 ± 18.9 230.4 ± 41.3 232.4 ± 48.0 188.4 ± 31.9 180.1 ± 35.1
ΔBaseline   72.2**
(54.6–89.8)
74.2**
(53.9–94.6)
30.2**
(17.0–43.4)
21.9*
(8.1–35.7)
Muscle Pain (mm) 21 Mean ± SD 15.3 ± 20.6 38.6 ± 25.6 33.6 ± 27.6 36.2 ± 25.3 21.4 ± 21.1
ΔBaseline   23.3**
(11.6–35.1)
18.3*
(5.7–31.0)
20.9**
(9.3–32.5)
6.2
(−3.5–15.9)
Joint Pain (mm) 21 Mean ± SD 8.7 ± 19.3 33.5 ± 21.3 31.2 ± 25.2 23.9 ± 23.2 16.4 ± 26.2
ΔBaseline   24.8**
(15.0–34.6)
22.5**
(10.9–34.0)
15.2*
(4.6–25.9)
7.7
(−4.3–19.7)
  1. Results adjusted for mean-centered baseline. Means reported with standard deviations. ΔBaseline indicates the change from baseline (T0) – reported with 95% confidence interval. *P < 0.01 vs baseline. **P < 0.001 vs baseline